Neurobiological and Genomic Predictors of Relapse in Depression

Brief summary (registry, in English)

The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters. The main questions it aims are: 1. When patients with depression treated with antidepressants, does their brain activity also become normal? If so, 2. Then, can we stop the antidepressant treatment and expect minimum repeat of depression? The participants who receive a specific antidepressant treatment will be asked to: * Undergo quantitative electroencephalography (qEEG), * Record Event-related potential (ERP), * Record Sleep EEG * Answer Hamilton Depression Rating Scale question their psychiatrists asked * Give blood sample for genetic analysis * Repeat the above mentioned procedures for at least 3 times during their treatment period. Researchers will compare the results of patients with the results of healthy controls.

What you commit to

• Study type: Observational
• Planned participants: 204
• From 1 Jan 2025 to the primary completion date, 1 Oct 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.